Here, we have shown the application of an EGFR-TKI-based fluorogenic probe (HX103) in fully quantifying active-EGFR to predict drug sensitivity in NSCLC patients with EGFR-activating mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.